A new vaccine allows pneumonia-causing bacteria to colonize inside the body, springing into action only if the bacteria pose a threat.
The breakthrough approach, coupled with the protein-based vaccine’s potential to counteract more than 90 strains of the bacteria, has the makings to override how vaccines have worked (destroying bacteria before colonization) since the days of Louis Pasteur.
Moreover, it offers what could be the most direct and broad response to pneumonia – the leading cause of death of children worldwide under the age of 5, according to the World Health Organization – as well as meningitis, sepsis and other serious infections caused by Streptococcus pneumoniae, a bacteria more commonly known as pneumococcus.
“These are very serious illnesses that we haven’t been able to completely suppress. The vaccine we’re developing could finally get that job done,” says Blaine A. Pfeifer, PhD, an associate professor of chemical and biological engineering at the University at Buffalo School of Engineering and Applied Sciences.
The work is described in a study, published today (June 6) in the Proceedings of the National Academy of Sciences, led by Pfeifer and UB alumnus Charles H. Jones, PhD, who is leading efforts to commercialize the vaccine at Buffalo-based startup Abcombi Biosciences.
“With conventional vaccines, the approach has been: ‘What bacteria do we want to target and how,’” says Jones, CEO and founder of Abcombi, and a former student of Pfeifer’s. “Our strategy is to shift the paradigm to which diseases do we want to prevent.”
Bacteria is still deadly
To treat and prevent illnesses caused by pneumococcus, doctors almost exclusively relied on penicillin and other common antibiotics. While still used, the effectiveness of these drugs has been waning for decades due to bacteria developing antibiotic resistance.
The situation led pharmaceutical companies to develop preventative vaccines, which have reduced deaths and illnesses, especially in developed nations. But pneumococcus remains a serious problem.
Pneumonia killed 1.3 million people worldwide in 2011, with the majority of deaths in Sub-Saharan Africa and South Asia. In the United States alone, pneumonia, meningitis and sepsis cause tens of thousands of deaths each year, according to the National Foundation for Infectious Diseases.
One reason for this is that current vaccines target only a small percentage – those known to cause the most severe infections – of the more than 90 strains of pneumococcus. These vaccines, which identify pneumococcus by a sugar coating that surround the bacteria, are 56 to 88 percent effective.
A new type of vaccine
The UB and Abcombi-led team took a different approach. Its vaccine identifies strains by proteins attached to the surface of pneumococcus. Laboratory tests show the vaccine can defend against more than 12 strains and that it’s 100 percent effective at promoting the appropriate immune response.
Computer simulations indicate the vaccine would be effective against all strains but additional tests are needed to confirm that.
“It’s like the arcade game Whac-A-Mole. Think of the mallet as a traditional vaccine. It can’t stop all the moles, or in our case, all the strains of bacteria at once,” Jones says. “But our vaccine does just that. It’s like a mallet with 90 heads that strikes all the moles simultaneously.”
The ability to fight numerous strains is important, Jones says, because developing new versions of existing vaccines is both costly and time-consuming.
The new vaccine also differs from what’s on the market by its response to the bacteria.
Current vaccines teach the immune system to indiscriminately destroy bacteria and other pathogens, thus preventing colonization. The approach works, but there is growing concern that it can create space within the body for new and potentially more harmful alternatives to establish residence – similar to antibiotic resistance resulting in new and more potent pathogens.
The new vaccine allows bacteria to exist as long as it causes no harm to body. It instructs the immune system to attack only when the surface proteins, mentioned above, break free of the bacterial coating.
“That’s the signal that this bacteria is becoming a troublemaker, that’s its threatening the body and that it’s necessary to fight back,” Pfeifer says.
Having proved the vaccine’s effectiveness in animals, Abcombi is now leading efforts to conduct human trials.
The Latest on: New vaccine
via Google News
The Latest on: New vaccine
- This New Vaccine Could Help Reduce Cat Allergieson August 17, 2019 at 2:14 am
Our days of sneezing when there’s a cat nearby may soon be reduced. Researchers at University Hospital Zurich in Switzerland have published a study claiming they have produced a vaccine that is given ...
- New York issues stricter rules on vaccine medical exemptionson August 16, 2019 at 10:28 pm
ALBANY, N.Y. (AP) — New York health officials have issued emergency regulations restricting medical exemptions from vaccination for children attending school or child care. The increased scrutiny of ...
- Confused About Who Should Get the HPV Vaccine, and When? The CDC Has New Recommendationson August 16, 2019 at 1:31 pm
The CDC reaffirmed that its prior recommendations for kids stand: boys and girls should get their first dose of the HPV vaccine when they are 11 or 12 years old, and a second dose six to 12 months ...
- DTP Vaccine Associated with Increased Rate of Total Mortality in Low-Income Countries Says Peter Gøtzsche in New Expert Reporton August 16, 2019 at 6:53 am
SHERIDAN, Wyo., Aug. 16, 2019 /PRNewswire/ -- DTP is one of the most common vaccines used in the world. In 2012, SAGE requested that the WHO review the evidence concerning the possible effects of ...
- Dr. Zorba Paster: New shingles vaccine is worth it for those 50 and olderon August 16, 2019 at 3:05 am
Dear Doc: I have post-herpetic nerve pain from a shingles infection five years ago. Will the new vaccine be beneficial? — Amy in Oklahoma City Dear Amy: Yes. Yes. Yes. The Centers for Disease Control ...
- New Cat Allergy Vaccine Could Save Sneezy Parents From Dander-Filled Kittenson August 15, 2019 at 8:04 am
As a parent, it’s only a matter of time before your kid begs you for a pet. It’s just going to happen, ok?! But all too often, allergies stand in the way. In fact, as many as three in 10 people with ...
- This New Vaccine May Prevent People From Being Allergic to Cats, and Talk About Good News!on August 15, 2019 at 7:45 am
As the proud owner of five cats, I can't imagine a world in which I couldn't pet and play with my four-legged friends every single day. But for some people with bad allergies, missing out on purrs and ...
- New vaccine could help those allergic to catson August 14, 2019 at 11:58 am
A new treatment, in the form of a vaccine, however, may be the key ending side-effects. Researchers have published results of a new study in The Journal of Allergy and Clinical Immunology that ...
- A new allergy vaccine could finally let anyone become a cat personon August 14, 2019 at 10:35 am
Cat people, rejoice: A new vaccine is in development that aims to significantly reduce symptoms brought on by allergies to fluffy felines. This isn’t just good news for everyone who wants to curl up ...
- New Chlamydia Vaccine Shows Promise In First Human Trialon August 14, 2019 at 6:54 am
Chlamydia is one of the most common sexually transmitted infections in the world, with doctors reporting 131 million new cases every year — but that number could drop dramatically thanks to a ...
via Bing News